AstraZeneca Patient Finder Suitability Analysis

Analysis Date: March 11, 2026

Prepared by: Ada Cockpit

Analysis Version: v4

Drugs Analyzed: 10 (4 Tier 1, 5 Tier 2, 1 No Fit)

Executive Summary

AstraZeneca's portfolio presents exceptional Patient Finder opportunities, particularly in oncology and rare disease. The company has 8-10 TIER 1/2 assets with strong fit scores, driven by:

Total Opportunity

$2.48 billion total addressable annual value globally (USA + DACH + ROW)

270,000+ addressable undiagnosed patients across portfolio

Ada Revenue Potential: $24.8M - $123.8M annually (1-5% penetration)

Top Opportunities

Portfolio Summary Table

Drug Indication Tier Fit Score Addressable Undiagnosed (USA) Ada Revenue Opportunity (Annual, 1-5%)
Soliris/Ultomiris PNH, aHUS, gMG, NMOSD TIER 1 9.5 4,693 $3.5M - $17.8M
CRYSVITA X-Linked Hypophosphatemia TIER 1 8.5 6,700 $4.9M - $24.6M
Strensiq Hypophosphatasia TIER 1 8.0 3,514 $1.9M - $9.7M
Tagrisso EGFR+ NSCLC TIER 1 7.5 5,000 $1.6M - $7.8M
Enhertu HER2+ Breast Cancer TIER 2 7.5 3,300 $775K - $3.9M
Tezspire/Fasenra Severe Asthma TIER 2 7.5 225,000 $14.3M - $71.3M
Imfinzi NSCLC/SCLC TIER 2 7.0 4,090 $922K - $4.6M
Calquence CLL, MCL TIER 2 6.5 1,360 $307K - $1.5M
Lynparza BRCA+ Cancers TIER 2 5.5 2,360 $677K - $3.4M
Farxiga T2D, HFpEF, CKD NO FIT 4.0 32,000,000 Mass-market, low per-patient economics

Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), NMOSD

Fit Score: 9.5 | Ada Surface Ability: 9 | Company Motivation: 10

Market Opportunity

USA Addressable Undiagnosed: 4,693 patients

DACH Addressable: 998 patients

ROW Addressable: 5,400 patients

Patient Finder Fee (USA): $40,000/patient/year

Ada Revenue Opportunity (USA):

  • 1% penetration: $1.88M/year
  • 5% penetration: $9.4M/year

Clinical Profile

Underdiagnosis Rate: 70% (only 30% of diagnosed PNH patients receive complement inhibitors)

Key Symptoms: Dark urine (PNH), acute kidney injury triad (aHUS), muscle weakness patterns (gMG)

Diagnostic Delay: PNH - years; aHUS - acute but delayed complement inhibitor initiation; gMG - 3-5 years to identify refractory cases

Treatment Duration: Lifelong complement inhibition

Commercial Context

Annual Revenue: ~$10B combined rare disease portfolio (Ultomiris Q4 2024: $1.1B, +33% YoY)

Competitive Pressure: High - Biosimilar eculizumab emerging 2026+, oral alternatives (iptacopan)

Patent Expiry: Soliris - LOE 2025-2026; Ultomiris - protected through 2030+

Pitch Hook: "5,000+ undiagnosed PNH, aHUS, and refractory gMG patients in the US are experiencing life-threatening complications - 70% never reach diagnosis. Ada can surface these ultra-rare patients when they search for fatigue, dark urine, or muscle weakness, generating $3-18M annually while protecting Ultomiris market share ahead of biosimilar competition."

Indication: X-Linked Hypophosphatemia (XLH)

Fit Score: 8.5 | Ada Surface Ability: 8 | Company Motivation: 9

Market Opportunity

USA Addressable Undiagnosed: 6,700 patients

DACH Addressable: 2,000 patients

ROW Addressable: 10,000 patients

Patient Finder Fee (USA): $36,000/patient/year

Ada Revenue Opportunity (USA):

  • 1% penetration: $2.41M/year
  • 5% penetration: $12.06M/year

Clinical Profile

Underdiagnosis Rate: 50% (mean diagnosis age ~6.1 years, many adults undiagnosed for decades)

Key Symptoms: Rickets + short stature + bone pain + dental abscesses (pediatric); bone pain + fractures + dental issues (adult)

Diagnostic Delay: 4-5 years pediatric, decades for adults

Treatment Duration: Lifelong FGF23 inhibition

Commercial Context

Annual Revenue: ~$300-500M (part of Alexion rare disease portfolio)

Competitive Pressure: Low - superior efficacy vs. conventional therapy, no direct competitors

Patent Expiry: Protected through 2030+ (orphan exclusivity)

Pitch Hook: "6,700+ XLH patients in the US suffer with misdiagnosed 'rickets' or 'osteomalacia' for years before correct diagnosis. Ada can identify vitamin D-resistant bone disease patterns and low phosphate, generating $2.4-12M annually for CRYSVITA while transforming lives with the only FGF23-targeted therapy."

Indication: Hypophosphatasia (HPP)

Fit Score: 8.0 | Ada Surface Ability: 7 | Company Motivation: 9

Market Opportunity

USA Addressable Undiagnosed: 3,514 patients

DACH Addressable: 540 patients

ROW Addressable: 2,700 patients

Patient Finder Fee (USA): $36,000/patient/year

Ada Revenue Opportunity (USA):

  • 1% penetration: $1.26M/year
  • 5% penetration: $6.33M/year

Clinical Profile

Underdiagnosis Rate: 60-70% (especially adult/mild forms; pediatric severe ~40%)

Key Symptoms: Rickets + premature tooth loss (pediatric); chronic bone pain + fractures + dental issues (adult)

Diagnostic Delay: Months to 1-2 years (pediatric severe); 5-10+ years (adult)

Treatment Duration: Lifelong enzyme replacement

Commercial Context

Annual Revenue: ~$400-600M (part of Alexion rare disease portfolio)

Competitive Pressure: None - monopoly position, only approved therapy

Patent Expiry: Protected through 2030+ (orphan exclusivity)

Pitch Hook: "3,500+ patients with life-altering Hypophosphatasia remain undiagnosed in the US - many suffering for years with misdiagnosed 'osteoporosis' or 'chronic pain.' Ada can identify distinctive symptom patterns (fractures + dental issues + bone pain) and low alkaline phosphatase, generating $1.3-6.3M annually for Alexion's monopoly Strensiq franchise."

Indication: EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Fit Score: 7.5 | Ada Surface Ability: 6 | Company Motivation: 9

Market Opportunity

USA Addressable Undiagnosed: 5,000 patients

DACH Addressable: 1,575 patients

ROW Addressable: 7,500 patients

Patient Finder Fee (USA): $14,640/patient/year

Ada Revenue Opportunity (USA):

  • 1% penetration: $732K/year
  • 5% penetration: $3.66M/year

Clinical Profile

Underdiagnosis Rate: 25% (EGFR testing compliance ~70-80%, plus late-stage detection gaps)

Key Symptoms: Persistent cough, hemoptysis, chest pain, shortness of breath, weight loss

Diagnostic Delay: 6-12 months from symptom onset, plus 2-4 weeks for EGFR testing

Treatment Duration: Until progression (median PFS 18-38 months metastatic, 3 years adjuvant)

Commercial Context

Annual Revenue: $7.25B globally (2025, +10% YoY)

Competitive Pressure: Moderate-High - Amivantamab combos threatening 1st-line share

Patent Expiry: US patents expire 2032-2035

Pitch Hook: "5,000+ EGFR+ NSCLC patients in the US remain undiagnosed due to late-stage detection and testing gaps. Ada can identify high-risk lung cancer symptoms early, accelerate diagnosis, and drive biomarker testing compliance - worth $730K-$3.7M annually to AstraZeneca as Tagrisso defends $7B+ franchise ahead of competitive threats."

Indication: HER2-positive Breast Cancer

Fit Score: 7.5 | Ada Surface Ability: 6 | Company Motivation: 9

Market Opportunity

USA Addressable Undiagnosed: 3,300 patients

Patient Finder Fee (USA): $13,200/patient/year

Ada Revenue Opportunity (USA): $436K - $2.18M/year (1-5% penetration)

Pitch Hook: "3,300+ HER2+ breast cancer patients in the US face delayed HER2 testing or treatment initiation. Ada can streamline post-diagnosis HER2 testing compliance and care navigation, supporting Enhertu's $2.8B US franchise and expansion into earlier treatment lines - worth $436K-$2.2M annually."

Indication: Severe Asthma (Tezspire: broad; Fasenra: eosinophilic)

Fit Score: 7.5 | Ada Surface Ability: 7 | Company Motivation: 8

Market Opportunity

USA Addressable Undiagnosed: 225,000 patients

Patient Finder Fee (USA): $4,060/patient/year

Ada Revenue Opportunity (USA): $9.14M - $45.68M/year (1-5% penetration)

Pitch Hook: "225,000+ severe asthma patients in the US are poorly controlled on high-dose inhalers without biologic therapy. Ada can identify uncontrolled asthma patterns (frequent attacks, ER visits, steroid dependence) and accelerate biologic evaluation - worth $9-46M annually for AstraZeneca's $2B+ Tezspire/Fasenra franchise."

Indication: NSCLC (stage III), SCLC, Biliary Tract Cancer

Fit Score: 7.0 | Ada Surface Ability: 6 | Company Motivation: 8

Market Opportunity

USA Addressable Undiagnosed: 4,090 patients

Patient Finder Fee (USA): $14,400/patient/year

Ada Revenue Opportunity (USA): $590K - $2.95M/year (1-5% penetration)

Pitch Hook: "4,000+ stage III/extensive-stage lung cancer patients in the US face diagnostic delays before receiving Imfinzi's life-extending therapy. Ada can identify high-risk lung cancer symptoms early and accelerate diagnosis, worth $590K-$3M annually as Imfinzi expands toward $6B+ franchise and new indications."

Indication: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma

Fit Score: 6.5 | Ada Surface Ability: 6 | Company Motivation: 7

Market Opportunity

USA Addressable Undiagnosed: 1,360 patients

Patient Finder Fee (USA): $15,196/patient/year

Ada Revenue Opportunity (USA): $207K - $1.03M/year (1-5% penetration)

Pitch Hook: "1,400+ undiagnosed CLL patients in the US are progressing without treatment. Ada can surface symptomatic CLL (lymph nodes, infections, fatigue) and accelerate diagnosis - worth $207K-$1M annually as Calquence defends $3.2B franchise against surging Brukinsa competition."

Indication: BRCA-mutated Ovarian, Breast, Prostate, Pancreatic Cancer

Fit Score: 5.5 | Ada Surface Ability: 5 | Company Motivation: 6

Market Opportunity

USA Addressable Undiagnosed: 2,360 patients

Patient Finder Fee (USA): $12,000/patient/year

Ada Revenue Opportunity (USA): $283K - $1.42M/year (1-5% penetration)

Strategic Context

Patent Expiry: US patents expire August 12, 2027; generic entry possible September 8, 2027

Note: LOE approaching reduces long-term strategic value, but near-term opportunity exists for BRCA testing navigation

Pitch Hook: "2,400+ BRCA+ ovarian and prostate cancer patients in the US are missing life-extending Lynparza due to genetic testing gaps. Ada can accelerate cancer diagnosis and BRCA testing completion, worth $283K-$1.4M annually - strategic value before 2027 LOE threatens Lynparza's $2.7B franchise."

Indication: Type 2 Diabetes, Heart Failure (HFpEF/HFrEF), Chronic Kidney Disease

Fit Score: 4.0 | Ada Surface Ability: 5 | Company Motivation: 3

Why NO FIT?

  • Mass-market disease: 32M+ undiagnosed across T2D, HFpEF, CKD - too broad, not niche
  • Low per-patient revenue: $3,000-4,000 net/year after rebates
  • Low Patient Finder fee: $240-480/patient/year (8-12%) - not economically attractive
  • Generic competition imminent: Patent expiry 2025-2028, LOE approaching
  • Detection via screening, not symptoms: HbA1c, eGFR, echo = routine lab/imaging
  • Company motivation low: AZ not investing aggressively pre-LOE

Recommendation: AVOID. Focus on rare disease and oncology assets with higher per-patient economics and longer exclusivity runways.

Key Findings & Recommendations

Strongest Opportunities

  1. Rare disease portfolio (Soliris/Ultomiris, Strensiq, CRYSVITA) is the highest-value Patient Finder opportunity:
    • 60-95% underdiagnosis rates
    • $32K-40K per patient annual fees
    • Distinctive, Ada-surfaceable symptom patterns
    • No generic competition
    • Very high company motivation (Alexion strategic pillar)
  2. Oncology biomarker testing gaps (Tagrisso EGFR, Enhertu HER2, Lynparza BRCA) represent large addressable populations:
    • 20-40% undertesting despite guidelines
    • $12K-15K per patient fees
    • Ada's role: pre-diagnosis symptom assessment + post-diagnosis testing navigation
    • Strategic urgency high for drugs facing LOE (Lynparza 2027, Tagrisso early 2030s)

Pitching Strategy

Next Steps

  1. Prioritize outreach: Alexion rare disease portfolio (Soliris/Ultomiris, Strensiq, CRYSVITA) as anchor deal
  2. Secondary: Tagrisso (EGFR testing compliance), Enhertu (HER2 testing navigation)
  3. Package: Offer multi-drug portfolio deal (rare disease + oncology bundle)
  4. Avoid: Farxiga and other mass-market assets

AstraZeneca Patient Finder Analysis - Ada Cockpit - March 2026

Analysis Version v4 | 10 Drugs Analyzed | 100+ Data Sources Cited

For internal use only. All prevalence, revenue, and pricing figures cited with source URLs in full markdown report.